GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (XSWX:BAX) » Definitions » Debt-to-EBITDA

Baxter International (XSWX:BAX) Debt-to-EBITDA : 6.39 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Baxter International Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Baxter International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was CHF2,341 Mil. Baxter International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was CHF10,251 Mil. Baxter International's annualized EBITDA for the quarter that ended in Mar. 2024 was CHF1,969 Mil. Baxter International's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 6.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Baxter International's Debt-to-EBITDA or its related term are showing as below:

XSWX:BAX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -20.12   Med: 3.09   Max: 8.59
Current: 8

During the past 13 years, the highest Debt-to-EBITDA Ratio of Baxter International was 8.59. The lowest was -20.12. And the median was 3.09.

XSWX:BAX's Debt-to-EBITDA is ranked worse than
91.86% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.245 vs XSWX:BAX: 8.00

Baxter International Debt-to-EBITDA Historical Data

The historical data trend for Baxter International's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Debt-to-EBITDA Chart

Baxter International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.19 3.00 8.36 -20.12 8.59

Baxter International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.30 16.02 15.39 5.29 6.39

Competitive Comparison of Baxter International's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Baxter International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Baxter International's Debt-to-EBITDA falls into.



Baxter International Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Baxter International's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2417.981 + 10004.006) / 1445.946
=8.59

Baxter International's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2340.572 + 10250.89) / 1969.136
=6.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Baxter International  (XSWX:BAX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Baxter International Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Baxter International's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxter International (XSWX:BAX) Business Description

Traded in Other Exchanges
Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.